Methylnaltrexone (MNTX) is a peripherally acting μ-opioid receptor antagonist and is currently indicated for the treatment of opioid-induced constipation in patients with advanced illness who are receiving palliative care, when response to laxative therapy has not been sufficient.
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Introduction
Methylnaltrexone (MNTX) is a quaternary derivative of the opioid antagonist, naltrexone (Brown and Goldberg, 1985) . Unlike naltrexone, this opioid receptor antagonist has restricted penetration across the blood-brain barrier (Brown and Goldberg, 1985; Yuan et al., 1996; Yuan et al., 1998) . Thus, it reduces the peripheral side effect of opioids without reversal of analgesia or the induction of opioid withdrawal. In healthy volunteers, intravenous MNTX effectively blocked acute morphine-induced delay in oral-cecal transit time without affecting analgesia (Yuan et al., 1996; Yuan et al., 2002) . A significant reversal of the gut transit delay in subjects dependent on chronic methadone treatment was also observed with intravenous MNTX (Yuan et al., 1998; Yuan et al., 1999; Yuan et al., 2000) . Unlike naltrexone, a structural analog of MNTX without the quarternary amine, which is extensively metabolized in humans (Wall et al., 1981; Wall et al., 1984) , MNTX is only minimally metabolized in humans (Chandrasekaran et al., 2010) .
It is well documented that sulfation is an important pathway in the biotransformation of xenobiotics such as drugs and endogenous compounds such as thyroid hormones, steroids, monoamine neurotransmitters and bile acids (Gamage et al., 2006; Matsunaga et al., 2006) .
Carbonyl reduction of aldehyde and ketone moieties may be catalyzed by alcohol dehydrogenases, aldo-keto reductases (AKRs), short-chain dehydrogenases/reductases (SDRs) including carbonyl reductase (CR), and quinone reductases .
Although these enzymes are involved in biological processes such as steroid and prostaglandin metabolism, drug detoxification, housekeeping, stress response and neurotransmission, and are considered potential drug targets liver microsomes or cytosol in 0.5 mL of 100 mM potassium phosphate buffer, pH 7.4, and were conducted in a shaking water bath at 37°C. After pre-incubation for 3 min, the reactions were initiated by the addition of an NADPH regenerating system. Control incubations were conducted in absence of the NADPH regenerating system. The NADPH regenerating system consisted of glucose-6-phosphate (2 mg/mL), glucose-6-phosphate dehydrogenase (0.8 units/mL) and NADP + (2 mg/mL). Incubations were stopped by the addition of 0.5 mL ice-cold acetonitrile. Samples were vortex-mixed. Denatured proteins were separated by centrifugation at 4300 rpm and 4°C
for 10 min (Model T21 super centrifuge, Sorvall). The supernatant was evaporated to a volume of about 0.4 mL under a nitrogen stream in a TurboVap LV evaporator (Caliper Life Sciences, Hopkinton, MA). The concentrated sample was centrifuged and duplicate aliquots (20 μL) of the supernatant were taken for determination of radioactivity by liquid scintillation as described later. This extraction method recovered greater than 85% of the radioactivity from the reaction mixture. An aliquot of the supernatant was analyzed by HPLC with radioactivity flow detection.
MNTX reduction in hepatic microsomal and cytosolic fractions was evaluated in different species. [ 14 C]MNTX (50 μM, 0.3-0.5 μCi/mL) was incubated with liver microsomes or cytosol (4 mg/mL) of mice, rats, dogs, monkeys and humans for 2 h as described above. Activity in the microsomal and cytosolic fractions in human intestine was also evaluated under the same conditions.
Conditions were optimized for kinetic study in liver cytosol of mice, rats, monkeys and humans.
Time course and protein-dependence experiments were conducted to determine the initial rate Table   1 . Similarly, time course, protein dependence and kinetics of naltrexone reduction to 6β-naltrexol in human liver cytosol were also studied under the conditions listed in Table 1, for comparison with MNTX. Mass spectral data for the metabolites was obtained with a Micromass Q-TOF API-US mass spectrometer (Waters Corp., Milford, MA). It was equipped with an electrospray ionization source and operated in the positive ionization mode. Full scan spectra were acquired from m/z 100 to 1500 with a scan time of 0.9 sec. The capillary and cone voltages were 3.5 kV and 25 V, respectively. The source block and desolvation gas temperatures were 120 °C and 350 °C, respectively. The desolvation gas flow was 900 L/h and the TOF-MS resolution was approximately 8,000 (m/∆m). Argon was used for collision activated dissociation experiments at a pressure setting of 13 psi and the collision offset for acquiring tandem mass spectra varied between 20 -35 eV depending on the metabolite. The quadrupole radio-frequency setting was 0.2.
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This article has not been copyedited and formatted. The final version may differ from this version. cytosol in the presence of NADPH, slightly lower activity was observed than with the NADPH regenerating system, while metabolites were not detected when NADH was used as the cofactor (data not shown).
Species differences were observed in metabolite profiles in liver cytosol ( Figure 1 ) and were generally consistent with previous in vivo metabolism observations (Chandrasekaran et al., 2010) . Metabolites formed in liver cytosol were identified by LC/MS and had the same retention times and mass spectra as those observed in human plasma as described elsewhere (Chandrasekaran et al., 2010) . Mass spectra data for MNTX and its metabolites identified in liver cytosol and enzyme preparations are summarized in Table 3 . In liver cytosol of mouse, monkey and human, both methyl-6α-naltrexol (M4) and methyl-6β-naltrexol (M5) were observed. However, M4 was observed in greater amounts than M5 in the cytosol of monkey and human, but in much lower amounts than M5 in mouse liver cytosol. Only M5 was observed in rat liver cytosol, and only a trace amount of M4 was observed in dog liver cytosol. Due to the low activity, a kinetic study was not conducted with dog liver cytosol. The capacity (V max /K m )
for the formation of M4 was much greater in the liver cytosol of monkey and human than in the liver cytosol of mouse and rat, while the capacity for the formation of M5 was greater in mouse liver cytosol than in liver cytosol of other species (Table 4) .
This article has not been copyedited and formatted. The final version may differ from this version. (Fig. 2) . The identity of the M2 metabolite peak was confirmed by mass spectrometry in comparison with synthetic standard of MNTX-3-sulfate (Chandrasekaran, 2010) . No products were detected when [ 
Discussion
The primary metabolic pathways for MNTX in humans are sulfation and carbonyl reduction (Chandrasekaran et al., 2010) . MNTX was metabolized via glucuronidation, hydroxylation, methylation, sulfation and carbonyl reduction in non-human species. The species differences in the carbonyl reduction of MNTX by hepatic cytosol in presence of NADPH were consistent with the in vivo data in mice, rat, dogs and humans. Both M4 and M5 were formed in liver cytosol of mice and humans. However, M4 was observed in a higher amount than M5 in human liver cytosol, which was consistent with human plasma profiles, while M4 was a minor isomer in mouse liver cytosol. Only trace amounts of M4 were observed in dog liver cytosol. The kinetic parameters in human liver cytosol also showed that the capacity for carbonyl reduction was about 100-fold greater for naltrexone than for MNTX. The kinetic data for the formation of 6β-naltrexol from naltrexone in human liver cytosol were also consistent with a literature report by Porter et al. (Porter et al., 2000) .
Of the five recombinant human sulfotransferase enzymes examined, only SULT1E1 and SULT2A1 catalyzed MNTX sulfation. SULT1E1 expressed in human liver and jejunum, is important for steroid homeostasis (Gamage et al., 2006) and also has high affinity for β-estradiol, estrone and a number of synthetic estrogens (Gamage et al., 2006) . SULT2A1, which is present in human liver, adrenal, small intestine and other organs, is responsible for the sulfation of hydroxysteroids including dehydroepiandrosterone, androgens, pregnenolone and bile acids (Gamage et al., 2006) . SULT1A1, 1A2 and 1A3, which are responsible for sulfation of phenolic compounds and catecholamines, showed no activity toward MNTX.
This article has not been copyedited and formatted. The final version may differ from this version. or 1C3 (Steckelbroeck et al., 2006) . Naltrexone reduction has been shown to be catalyzed by AKR1C4, with minor contribution from AKR1C1 and 1C2 (Breyer-Pfaff and Nill, 2004) .
Formation of M4 and M5 was inhibited by up to 67% by the AKR1C2 selective inhibitor 5β-cholanic acid-3α,7α-diol (Breyer-Pfaff and Nill, 2004) , and by medroxyprogesterone acetate, which inhibits AKR1C1, 1C2 and 1C4 . 5β-Cholanic acid-3α,7α-diol and medroxyprogesterone acetate inhibited naltrexone reduction by about 34% and 47% at 100 μM, respectively. Flufenamic acid, a selective inhibitor of AKR1C1, 1C2 and 1C3, and a weak inhibitor of AKR1C4 (Steckelbroeck et al., 2004; Steckelbroeck et al., 2006) , inhibited the formation of M5, but increased the formation of M4 up to 2.1-fold in a concentration-dependent manner, while little inhibitory effect was observed on 6β-naltrexol formation. Indomethacin is an unspecific inhibitor of both AKRs and CR, and showed low to moderate potency with either substrate (Gebel and Maser, 1992; Maser et al., 2000) . Indomethacin had no inhibitory effect on 6β-naltrexol formation, slightly inhibited M5 formation while increased M4 formation. The lack of inhibitory effect by phenobarbital (an inhibitor of AKR1A1 and AKR1B1) on the reduction of MNTX and naltrexone confirmed that the AKRs capable of reducing xenobiotic ketones are primarily the AKR1C subfamily in humans . Altogether, the data indicated that multiple isoforms in the AKR1C subfamily are responsible for MNTX reduction, with major contribution probably from AKR1C4, which is virtually liver-specific (Penning et al., 2000) .
This article has not been copyedited and formatted. The final version may differ from this version. Ethacrynic acid, menadione and quercetin, the inhibitors of CR or SDR , did not appear to affect the reduction of either MNTX or naltrexone significantly. Since Breyer-Pfaff and Nill have showed that CR was not involved in the reduction of naltrexone (Breyer-Pfaff and Nill, 2004) , the decreases in the reduction of MNTX and naltrexone may be due to non-specific inhibition by these inhibitors. Incubations with the chemical inhibitors (4-methylpyrazole and dicumarol, respectively) of alcohol dehydrogenase and quinone oxidoreductase showed that these two enzymes are not involved in the reduction of MNTX. However, the quinone oxidoreductase inhibitor dicumarol increased M4 formation by 1.9-fold at 100 μM, similar to flufenamic acid.
Stereoselective effects on MNTX reduction were observed with flufenamic acid, indomethacin and dicumarol. While they inhibited the formation of the 6β-epimer, they enhanced the formation of the 6α-epimer. Such effects of these inihibitors were not observed with naltrexone, since it was reduced only to one epimer, 6β-epimer. Enzyme activation in vitro has been well documented for cytochrome P450 (CYP) isoforms, particularly CYP3A (Fayz and Inaba, 1998) .
Various mechanisms have been proposed for the activation of CYP enzymes. An activator such as 7,8-benzoflavone may enhance the interaction of cytochrome P450 reductase and cytochrome P450 (Huang et al., 1981) . Flavones are allosteric effectors that may increase catalytic efficiency by lowering the K m and increasing the V max (Schwab et al., 1988) . Shou et al. demonstrated simultaneous binding of two substrates to the P450 active site (Shou et al., 1995) . Binding of a substrate to the active site can alter the orientation of another substrate, thereby changing the regioselectivity of the metabolism. Enzyme activation of P450 reductase and cytochrome b5
reductase by ethacrynic acid, dipyridamole and indomethacin has also been reported for the reduction of 3′-azido-3′-deoxythymidine to 3′-amino-3′-deoxythymidine (Fayz and Inaba, 1998) .
This article has not been copyedited and formatted. The final version may differ from this version. However, activation of AKR enzyme activity has not been reported. AKRs share a common (α/β) 8 -barrel three-dimensional fold, with highly conserved nicotinamide-cofactor-binding pocket and active site (Jez et al., 1997; Sanli et al., 2003) . Jez et al. proposed that the three loops on the C-terminal side of the barrel play potential roles in determining the positional and stereospecificity of the reaction (Jez et al., 1997) . Studies have shown that the active site of AKRs adapts itself to bind tightly to different inhibitors (Urzhumtsev et al., 1997; El-Kabbani et al., 1998) . White et al. examined the X-ray crystal structures of AKR1C3 complexed with indomethacin or flufenamic acid (Lovering et al., 2004) . One molecule of indomethacin is bound in the active site, whereas flufenamic acid binds to both the active site and the β-hairpin loop, at Tables   Table 1. Initial rate conditions and incubation conditions used to measure kinetic parameters for MNTX reduction to methyl-6α-naltrexol (M4) and methyl-6β-naltrexol (M5) in liver cytosol of mice, rats, monkeys and humans, and naltrexone reduction to 6β-naltrexol in human liver cytosol 302, 284, 227, 199, 112, 55 M2 14.0 436 438 418, 382, 356, 302, 284, 227, 199, 112, 55 M4 20.5 358 361 340, 304, 286, 229, 201, 112, 55 M5 25.5 358 361 340, 304, 286, 229, 201, 112, 55 This article has not been copyedited and formatted. The final version may differ from this version. 
